These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 38102573)

  • 21. Low-Dose Mycophenolate Mofetil for Treatment of Neuromyelitis Optica Spectrum Disorders: A Prospective Multicenter Study in South China.
    Huang Q; Wang J; Zhou Y; Yang H; Wang Z; Yan Z; Long Y; Yin J; Feng H; Li C; Lu Z; Hu X; Qiu W
    Front Immunol; 2018; 9():2066. PubMed ID: 30258442
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of efficacy and tolerability of first-line therapies in NMOSD.
    Poupart J; Giovannelli J; Deschamps R; Audoin B; Ciron J; Maillart E; Papeix C; Collongues N; Bourre B; Cohen M; Wiertlewski S; Outteryck O; Laplaud D; Vukusic S; Marignier R; Zephir H;
    Neurology; 2020 Apr; 94(15):e1645-e1656. PubMed ID: 32170036
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Efficacy and safety of mycophenolate mofetil in treating neuromyelitis optica spectrum disorder: a multicenter, prospective, self-control study in Guangzhou City].
    Huang Q; Wang YG; Shu YQ; Yang H; Wang ZH; Yan ZW; Long YM; Yin J; Feng HY; Li CX; Lu ZZ; Hu XQ; Qiu W
    Zhonghua Yi Xue Za Zhi; 2018 Jun; 98(21):1664-1668. PubMed ID: 29925143
    [No Abstract]   [Full Text] [Related]  

  • 24. Characteristic of gut microbiota in southeastern Chinese patients with neuromyelitis optica spectrum disorders.
    Zhang J; Xu YF; Wu L; Li HF; Wu ZY
    Mult Scler Relat Disord; 2020 Sep; 44():102217. PubMed ID: 32534438
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost effectiveness of rituximab and mycophenolate mofetil for neuromyelitis optica spectrum disorder in Thailand: Economic evaluation and budget impact analysis.
    Aungsumart S; Apiwattanakul M
    PLoS One; 2020; 15(2):e0229028. PubMed ID: 32050011
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of mycophenolate mofetil therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis.
    Songwisit S; Kosiyakul P; Jitprapaikulsan J; Prayoonwiwat N; Ungprasert P; Siritho S
    Sci Rep; 2020 Oct; 10(1):16727. PubMed ID: 33028926
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dysbiosis of gut microbiota in patients with neuromyelitis optica spectrum disorders: A cross sectional study.
    Shi Z; Qiu Y; Wang J; Fang Y; Zhang Y; Chen H; Du Q; Zhao Z; Yan C; Yang M; Zhou H
    J Neuroimmunol; 2020 Feb; 339():577126. PubMed ID: 31841737
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders.
    Montcuquet A; Collongues N; Papeix C; Zephir H; Audoin B; Laplaud D; Bourre B; Brochet B; Camdessanche JP; Labauge P; Moreau T; Brassat D; Stankoff B; de Seze J; Vukusic S; Marignier R;
    Mult Scler; 2017 Sep; 23(10):1377-1384. PubMed ID: 27885065
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Different monoclonal antibodies and immunosuppressants administration in patients with neuromyelitis optica spectrum disorder: a Bayesian network meta-analysis.
    Yin Z; Qiu Y; Duan A; Fang T; Chen Z; Wu J; Wang Z; Chen G
    J Neurol; 2023 Jun; 270(6):2950-2963. PubMed ID: 36884069
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Perturbed microbial ecology in neuromyelitis optica spectrum disorder: Evidence from the gut microbiome and fecal metabolome.
    Xie Q; Sun J; Sun M; Wang Q; Wang M
    Mult Scler Relat Disord; 2024 Oct; 92():105936. PubMed ID: 39418776
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rituximab-induced gut microbiota changes in Chinese neuromyelitis optica spectrum disorders.
    Chen H; Xu Z; Zhou Y; Jiang YH; Chen J; Xiong Y; Zhou M; Wu X; Hong D
    Mult Scler Relat Disord; 2024 Jun; 86():105606. PubMed ID: 38636269
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of mycophenolate mofetil for steroid reduction in neuromyelitis optica spectrum disorder: a prospective cohort study.
    Akatani R; Chihara N; Koto S; Mori S; Kurimoto T; Nakamura M; Tachibana H; Otsuka Y; Ueda T; Omori T; Sekiguchi K; Matsumoto R
    Immunol Med; 2024 Jun; 47(2):85-92. PubMed ID: 38235761
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationship between Azathioprine metabolites and therapeutic efficacy in Chinese patients with neuromyelitis optica spectrum disorders.
    Li X; Mei S; Gong X; Zhou H; Yang L; Zhou A; Liu Y; Li X; Zhao Z; Zhang X
    BMC Neurol; 2017 Jul; 17(1):130. PubMed ID: 28679367
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and efficacy of mycophenolate mofetil in treating neuromyelitis optica spectrum disorders: a protocol for systematic review and meta-analysis.
    Han M; Nong L; Liu Z; Chen Y; Chen Y; Meng H; Qin Y; Wang Z; Jin M
    BMJ Open; 2020 Nov; 10(11):e040371. PubMed ID: 33257483
    [TBL] [Abstract][Full Text] [Related]  

  • 35. GV-971 attenuates the progression of neuromyelitis optica in murine models and reverses alterations in gut microbiota and associated peripheral abnormalities.
    Yang X; Zhangyi Z; Yu A; Zhou Q; Xia A; Qiu J; Cai M; Chu X; Li L; Feng Z; Luo Z; Sun G; Zhang J; Geng M; Chen S; Xie Z
    CNS Neurosci Ther; 2024 Jul; 30(7):e14847. PubMed ID: 38973196
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of inosine monophosphate dehydrogenase-1 gene polymorphisms on mycophenolate mofetil effectiveness in neuromyelitis optica spectrum disorder patients.
    Liu L; Luo Z; Liu F; Shang D; Qiu D; Jiao X; Zhou X; Chen S; Wu J; Li J
    Mult Scler Relat Disord; 2021 Apr; 49():102779. PubMed ID: 33524926
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Role of Gut Microbiota in Neuromyelitis Optica Spectrum Disorder.
    Yao SQ; Yang X; Cen LP; Tan S
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542152
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial.
    Zhang C; Zhang M; Qiu W; Ma H; Zhang X; Zhu Z; Yang CS; Jia D; Zhang TX; Yuan M; Feng Y; Yang L; Lu W; Yu C; Bennett JL; Shi FD;
    Lancet Neurol; 2020 May; 19(5):391-401. PubMed ID: 32333897
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder.
    Kunchok A; Malpas C; Nytrova P; Havrdova EK; Alroughani R; Terzi M; Yamout B; Hor JY; Karabudak R; Boz C; Ozakbas S; Olascoaga J; Simo M; Granella F; Patti F; McCombe P; Csepany T; Singhal B; Bergamaschi R; Fragoso Y; Al-Harbi T; Turkoglu R; Lechner-Scott J; Laureys G; Oreja-Guevara C; Pucci E; Sola P; Ferraro D; Altintas A; Soysal A; Vucic S; Grand'Maison F; Izquierdo G; Eichau S; Lugaresi A; Onofrj M; Trojano M; Marriott M; Butzkueven H; Kister I; Kalincik T
    Mult Scler Relat Disord; 2020 Feb; 38():101868. PubMed ID: 31877445
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A meta-analysis comparing first-line immunosuppressants in neuromyelitis optica.
    Giovannelli J; Ciron J; Cohen M; Kim HJ; Kim SH; Stellmann JP; Kleiter I; McCreary M; Greenberg BM; Deschamps R; Audoin B; Maillart E; Papeix C; Collongues N; Bourre B; Laplaud D; Ayrignac X; Durand-Dubief F; Ruet A; Vukusic S; Marignier R; Dauchet L; Zephir H;
    Ann Clin Transl Neurol; 2021 Oct; 8(10):2025-2037. PubMed ID: 34505407
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.